Report: Australia 60% cheaper than US for clinical trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/AlexKosev)
(Image: iStock/AlexKosev)

Related tags: Clinical trials, Clinical trial, Contract research organization

With a tax incentive program making clinical trials up to 60% more cost-effective, Australia is a “gateway” to larger studies throughout Asia, says CRO.

According to the report published​ by Frost & Sullivan, the clinical trials market is expected to reach $615m by 2019, growing at a CAGR of 12%. Additionally, early phase clinical trials have been growing at nearly twice this rate and growth is expected to continue.

The magnitude of Australia’s cost competitiveness was quite surprising when we saw the like-for-like comparison of a benchmark early phase clinical trial in the US versus Australia​,” Novotech Asia COO, Dr. John Moller told

Novotech, an Australian contract research organization (CRO), recently partnered with Deloitte to brief early stage companies on the benefits of tax benefits in the country – which can bring cost savings of up to 60%, compared to clinical trials in the US according to the report.

Often Australia is perceived as high cost but it is possibly the most cost-effective destination in the world​,” explained Moller, who said the cost differential is driven by a government cash rebate for research and development, the efficiency of Australian research providers, as well as foreign exchange rate differences. 

Australian currency was probably overvalued for a number of years during the commodities boom but it has now returned to its long-term average​,” he added.

A gateway to Asia

The CRO has been seeing an increasing interest from sponsors who view Australia as a “gateway​” for conducting larger regional studies in Asia, Moller said.

Australia has a very close relationship with many Asian countries with geographical proximity, overlapping time zones and an increasingly high level of cultural and business understanding​,” he explained.

Notably, Asia has a population of 4 billion people, 2 billion of whom are in readily accessible urban areas. 

This is very attractive for sponsors who are keen to accelerate their trials in a high quality environment​,” said Moller, who added that a number of clients are adopting a regional strategy wherein “they look for early recruitment and potentially announceable milestones from Australia and New Zealand with high volume recruitment from a number of Asian counties​.” 

With “such strong growth in this trend​,” Moller said the company has moved the majority of its activity to Asia.

Continuing improvement

Moller said there have been several improvements over the past 10 years in clinical trial efficiently, including advances in online submissions and standard clinical trial agreements.

The country has also implemented a National Mutual Acceptance framework, which Moller explained means scientific and ethical reviews are mutually accepted by 90% of clinical trial sites. 

Clinical trial competition can therefore be one of the biggest challenges particularly in some ‘hot’ therapeutic areas, or where prevalence rates in Australia are low​,” he added.

As for the future, Moller said the next five years will see continued improvement in efficiency, with implementation of standardized costing between sites and greater consistency in policies at a governance level.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more